Go to the list of all blogs
Anna G's Avatar
published in Blogs
May 21, 2023
Analyzing the Downturn: Unveiling the Story Behind Hims & Hers Health's (HIMS) -12.69% Monthly Descent

Analyzing the Downturn: Unveiling the Story Behind Hims & Hers Health's (HIMS) -12.69% Monthly Descent

Unlocking the Power of Artificial Intelligence to Make Trading Decisions with Tickeron's AI Robots.

In the competitive realm of healthcare and personal care, Hims & Hers Health (HIMS) faced a challenging month, witnessing a significant downturn of -12.69% and closing at $9.77 per share. This blog post aims to unravel the story behind Hims & Hers Health's notable setback, shedding light on the broader trends within the Household/Personal Care Industry. Join us as we dive into the analysis, examining the factors that contributed to the company's descent and exploring the market landscape that influenced its performance.

Understanding the Household/Personal Care Industry: To gain insights into Hims & Hers Health's performance, it is essential to understand the dynamics of the Household/Personal Care Industry. Our analysis of 95 stocks in this sector reveals that 47.37% exhibited an Uptrend, while 52.63% experienced a Downtrend. This industry overview sets the stage for comprehending the specific challenges and opportunities faced by Hims & Hers Health.

Factors Impacting Hims & Hers Health's Descent: Multiple factors may have influenced Hims & Hers Health's -12.69% monthly decline. Market conditions, competitive pressures, regulatory changes, or internal operational factors could have played a role in the company's setback. By examining these factors in detail, we can gain valuable insights into the circumstances that impacted Hims & Hers Health's performance.

Navigating the Landscape of Household/Personal Care: As investors evaluate the impact of Hims & Hers Health's descent, it becomes crucial to navigate the Household/Personal Care Industry with a discerning eye. Understanding the current market outlook, identifying potential opportunities, and assessing the risks associated with the sector are vital considerations for informed decision-making. This blog post provides valuable insights and strategies to help investors navigate the ever-evolving landscape of the Household/Personal Care Industry amidst Hims & Hers Health's downturn.

Hims & Hers Health's -12.69% monthly descent serves as a reminder of the volatility and challenges inherent in the Household/Personal Care Industry. By analyzing the broader market trends and uncovering the factors that influenced Hims & Hers Health's performance, investors can gain a comprehensive understanding of the landscape. In an industry that continues to evolve rapidly, staying informed, adapting to market conditions, and identifying potential opportunities while managing risks are crucial for investors seeking success in the Household/Personal Care sector.

Related Ticker: HIMS

HIMS in upward trend: price rose above 50-day moving average on March 13, 2026

HIMS moved above its 50-day moving average on March 13, 2026 date and that indicates a change from a downward trend to an upward trend. In of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on March 04, 2026. You may want to consider a long position or call options on HIMS as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HIMS just turned positive on February 25, 2026. Looking at past instances where HIMS's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for HIMS moved out of overbought territory on March 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HIMS broke above its upper Bollinger Band on March 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HIMS entered a downward trend on March 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HIMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.438) is normal, around the industry mean (25.509). P/E Ratio (48.569) is within average values for comparable stocks, (64.566). Projected Growth (PEG Ratio) (2.974) is also within normal values, averaging (1.971). HIMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (2.725) is also within normal values, averaging (112.957).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.89B. The market cap for tickers in the group ranges from 2.12K to 64.54B. MKKGY holds the highest valuation in this group at 64.54B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -1%. HIMS experienced the highest price growth at 57%, while CVSI experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 232%. For the same stocks of the Industry, the average monthly volume growth was 8% and the average quarterly volume growth was 11%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 66
Price Growth Rating: 60
SMR Rating: 79
Profit Risk Rating: 90
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
HIMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. HIMS showed earnings on February 23, 2026. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a company, which is involved in real estate investment trusts

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
2269 Chestnut Street
Phone
+1 415 851-0195
Employees
658
Web
https://www.forhims.com
Interact to see
Advertisement
Dive into the complexities of the miscellaneous sector as we uncover the trajectories of major players like $YETI, $TUP, and $DOV. Despite a significant 20.4% gain in just a month, not everything is as rosy as it seems. Read on to decipher our sell recommendations and where these tickers might be headed next.
Financial Learning Models (FLMs) and machine learning (ML) to operate at unprecedented speeds. These agents, now optimized for 5-minute (M5) timeframes, have demonstrated extraordinary annualized returns, with the top agent exceeding +160%.
AI-Driven Market Insights A.I.dvisor’s latest analysis compares SPY and VOO, two leading ETFs, revealing near-identical year-to-date (YTD) gains of 9.82% for SPY and 9.87% for VOO, a 99% parity.
Tickeron, a leader in AI-driven financial technology, today announced the launch of its advanced AI Trading Agents, delivering real-time trading signals and sophisticated money management for retail and institutional traders. Powered by Financial Learning Models (FLMs) and machine learning, these agents operate across 5-, 15-, and 60-minute timeframes, achieving annualized returns of up to 145% on select portfolios.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, today announced the exceptional performance of its AI Trading Agents, achieving annualized returns of up to 162%, profitable trade percentages as high as 90.51%, and a robust profit factor across multiple assets.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, proudly announces the exceptional performance of its AI Trading Agents, delivering annualized returns of up to 188% on a 5-minute timeframe.
#artificial_intelligence
Tickeron, a leader in AI-driven financial tools, today announced the launch of its advanced Pattern Search Engine (PSE), a revolutionary platform that scans 39 distinct trading patterns across stocks, penny stocks, ETFs, crypto, and forex.
#artificial_intelligence
AI trading bots represent the pinnacle of financial technology innovation, transforming how traders and investors interact with global markets.
#artificial_intelligence
As a financial analyst, writer, and AI specialist, I've always pushed for innovations that merge artificial intelligence with actionable trading tools. In the fast-paced world of modern markets, where volatility demands quick decisions, Tickeron's new "My Trades Aggregator (from AI Robots Followed)" aggregator stands out as a revolutionary feature.
#artificial_intelligence#trading
Tickeron, a leading provider of AI-driven trading solutions, is thrilled to announce the exceptional performance of its AI Trading Agents, delivering outstanding results across multiple high-profile stocks.
#artificial_intelligence
Tickeron, a leader in AI-driven financial technologies, today announced groundbreaking results from its AI Crypto Trading Virtual Agents. These innovative tools provide real-time trading signals, integrated money management, and customizable balances, all powered by advanced machine learning algorithms operating on 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technologies, today announced the launch of its advanced AI Trading Brokerage Agents. These cutting-edge tools deliver real-time trading signals powered by machine learning, utilizing tick-level brokerage data and precise trade amounts across 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
This remarkable rally represents far more than typical market volatility – it signals a fundamental transformation in investor sentiment toward AI connectivity infrastructure and the critical role of semiconductor-based solutions in enabling next-generation artificial intelligence systems
Tickeron, a leader in AI-driven financial tools, today announced the launch of its comprehensive subscription package combining AI Trading Robots for cryptocurrencies with Real-Time Patterns (RTP) analysis.
#artificial_intelligence
Kinross Gold Corporation (KGC), a leading Canada-based gold producer, yielded approximately 2.1 million gold equivalent ounces in 2024.
#artificial_intelligence
Tickeron, a leader in AI-driven financial technologies, today announced impressive results from its AI Trading Agent focused on the iShares U.S. Aerospace & Defense ETF (ITA). Over 123 days, the agent achieved an annualized return of +48%, generating $14,104 in closed trades profit and loss (P/L).
#artificial_intelligence
Tickeron, a pioneer in AI-powered trading solutions, today unveiled groundbreaking results from its 5-minute AI Trading Agent focused on Hubbell Incorporated (HUBB). In just 68 days, the agent delivered an impressive +98% annualized return and $12,899 in closed trades profit/loss (P/L), showcasing the transformative power of machine learning in stock trading.
#artificial_intelligence
In the fast-paced world of stock trading, where market volatility can swing fortunes overnight, Tickeron emerges as a beacon for investors seeking reliable guidance. As a leading provider of AI-powered trading solutions,
#artificial_intelligence
The company's journey from a struggling clean energy stock trading near multi-year lows to a market leader commanding a $12.9 billion valuation demonstrates the convergence of technological breakthroughs, strategic partnerships, regulatory tailwinds, and the explosive growth of AI-driven data centers that require reliable, on-site power solutions.
Palantir Technologies (NASDAQ: PLTR) has delivered one of the most remarkable performances in the technology sector during 2025, with its stock price surging approximately 145% from the April 7, 2025 low of $66.12 to the September 9, 2025 closing price of $162.36.